Icosapent Ethyl · Vascepa, AMR-101

What is Icosapent Ethyl?

Icosapent ethyl (Vascepa) is a highly purified ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA). It reduces serum triglycerides through multiple mechanisms including enhanced triglyceride clearance, increased beta-oxidation, and inhibition of hepatic triglyceride synthesis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Vascepa, AMR-101

Drug type

Small molecule

Pathways

triglyceride synthesis and secretion, triglyceride clearance, beta-oxidation, lipogenesis, platelet aggregation

Therapy area

Cardiovascular, Metabolic

Developer

Amarin Pharms (AMRN)

FDA status

Approved as Vascepa (July 26, 2012), NDA202057 · FDA label

UNII

6GC8A4PAYH

✅ FDA-approved uses

• Reduce risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevate
• Reduce triglyceride levels in adult patients with severe hypertriglyceridemia

From the indications section of the FDA label (version of Mar 23, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AtherosclerosisCardiovascular DiseasesCOVID19DyslipidemiasHypertriglyceridemiaLipid DisorderTriglycerides HighUpper Respiratory Tract Infections

Sources

• FDA label (DailyMed)
• FDA label Vascepa (2026-03-23), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT01047683
• ClinicalTrials.gov NCT01047683
• ClinicalTrials.gov NCT03885661
• ClinicalTrials.gov NCT04460651

Updated Oct 3, 2026. Something wrong or missing? Report it on the AMRN page.